-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lymphocyte activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct suppressive immune checkpoints that can lead to T cell exhaustion
.
The combination of riralimumab (LAG-3 blocking antibody) and nivolumab (PD-1 blocking antibody) has been shown to be safe and has antitumor activity in previously treated melanoma patients, However, their safety and activity in previously untreated melanoma patients requires further investigation
immunity
In this phase 2-3, global, double-blind, randomized trial, researchers evaluated a fixed-dose intravenous injection of renalizumab every 4 weeks and sodium Efficacy of combination therapy with nivolumab versus nivolumab alone in patients with previously untreated metastatic or unresectable melanoma
.
The primary endpoint of the study was progression-free survival as assessed by a blinded independent review
Median progression-free survival was 10.
1 months (95% CI, 6.
4 to 15.
7) for patients treated with the rilagimab–nivolumab combination versus nivolumab alone was 4.
6 months (95% CI, 3.
4 to 5.
6) (hazard ratio for progression or death, 0.
75 [95% CI, 0.
62 to 0.
92]; log-rank test P=0.
006)
.
The 12-month progression-free survival rate was 47.
7% (95% CI, 41.
8 to 53.
2) for patients treated with the rilagimab-nivolumab combination versus 36.
0% (95% CI, 41.
8 to 53.
2) for patients treated with nivolumab alone.
30.
5 to 41.
6)
.
Progression-free survival in key subgroups was better than that of the riralimumab-nivolumab combination compared with nivolumab alone
CONCLUSIONS: In patients with previously untreated metastatic or unresectable melanoma, inhibition of the two immune checkpoints, LAG-3 and PD-1, resulted in greater progression-free survival than inhibition of PD-1 alone.
benefit
.
No new safety events occurred with the combination therapy of rilagimab and nivolumab
In patients with previously untreated metastatic or unresectable melanoma, inhibition of the two immune checkpoints, LAG-3 and PD-1, resulted in a greater benefit in progression-free survival than inhibition of PD-1 alone
Original Source: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma Leave a comment here
